These results clearly demonstrate that DF2755A can prevent the onset and the development of the peripheral neuropathy induced by chronic CYP administration while having no significant effects on bladder inflammation in this model that is characterized by no inflammatory infiltrate. This evidence concerns the gene PPIG and peripheral neuropathy.